The Transfusion News email arrived today:
 February 6, 2019Immunotherapy, the use of humanized monoclonal antibodies, is a promising therapy that works in conjunction with the patient’s own immune system to target and mark cancerous cells for destruction. Anti-CD38, or daratumumab, targets the CD38 protein expressed on certain types of cancer cells. Anti-CD38, unfortunately, also interferes [Read More] |
||||
 February 6, 2019 | BBGuy PodcastFor the last few years, blood bankers have been saying, “Anti-CD47 is coming, and I hear it’s really going to mess up our testing!” Well, it’s here, and we were right! Dr. Connie Westhoff tells us what we can and can’t do to make it all better. [Listen Now] |
||||
|
||||
 Click
“Join” on the “Transfusion Medicine Questions” page to have the
“Question of the Day” emailed to you every Monday, Wednesday and Friday.
[Learn More] |
||||
 January 30, 2019Based on hemovigilance data from the National Healthcare Safety Network (NHSN), viral transfusion-transmitted infections (TTI) are rare while bacterial contamination of platelets and transfusion-transmitted babesiosis occur more frequently. The NHSN Hemovigilance Module began monitoring infections [Read More] |
No comments:
Post a Comment